Archives of Osteoporosis

, Volume 7, Issue 1–2, pp 237–246 | Cite as

Epidemiological burden of postmenopausal osteoporosis in France from 2010 to 2020: estimations from a disease model

  • H. Cawston
  • M. Maravic
  • P. Fardellone
  • A. Gauthier
  • J. A. Kanis
  • J. Compston
  • F. Borgström
  • C. Cooper
  • E. McCloskey
Original Article



This article estimates the present and future burden of postmenopausal osteoporosis in France in women aged 50 years and over.


We adapted an existing model developed for Sweden to France. For each year of the study from 1970 to 2020, the ‘incident cohort’ (women experiencing a first osteoporotic fracture) was identified and run through a Markov model using annual cycles. Health states were based on the number of fractures (hip, vertebral, non-hip non-vertebral) and deaths. Transition probabilities reflected fracture site-specific risks of subsequent fractures and of death. Country-specific model inputs included population size and life tables from 1970 to 2020 and incidence of hip fracture.


The model estimated that the number of postmenopausal osteoporotic women was expected to increase from 3.0 million to 3.4 million between 2010 and 2020 (+15.3 %). Assuming that the incidence of fracture by age group does not change over time, the model predicted that the overall number of osteoporotic fractures would increase from 204,234 fractures in 2010 to 241,261 in 2020 (+18.1 %), hip (20.3 %), vertebral (19.0 %) and non-hip non-vertebral fractures (17.0 %).


The aging of the population is expected to drive a marked increase in the prevalence of osteoporosis and in the number of osteoporotic fractures. These data may assist future planning for appropriate heath care provision.


Bone mineral density Epidemiology Fracture France Osteoporosis T score 


  1. 1.
    Anonymous (1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646–650CrossRefGoogle Scholar
  2. 2.
    Kanis JA on behalf of the World Health Organisation Scientific Group (2007) Assessment of osteoporosis at the primary health care level. World Health Organisation Collaborating Center for Metabolic Bone diseases University of Sheffield, UK. Available at.
  3. 3.
    Programme National Nutrition Santé (PNNS) (2010) Rapport du Haut Comité de santé Publique : “Pour une politique nutritionnelle de santé publique en France”. DREESGoogle Scholar
  4. 4.
    Maravic M, Taupin P, Landais P, Roux C (2011) Change in hip fracture incidence over the last 6 years in France. Osteoporos Int 22:797–801PubMedCrossRefGoogle Scholar
  5. 5.
    Maravic M, Le BC, Landais P, Fardellone P (2005) Incidence and cost of osteoporotic fractures in France during 2001. A methodological approach by the national hospital database. Osteoporos Int 16:1475–1480PubMedCrossRefGoogle Scholar
  6. 6.
    Gauthier A, Kanis JA, Martin M, Compston J, Borgstrom F, Cooper C, McCloskey E (2010) Development and validation of a disease model for postmenopausal osteoporosis. Osteoporos Int 22:771–780PubMedCrossRefGoogle Scholar
  7. 7.
    World Health Organisation (1994) Assessment of fracture risk and its application to screening for postmenauposal osteoporosis. World Health Organisation, Geneva Technical Report series no. 843:1–129Google Scholar
  8. 8.
    Melton LJ III, Thamer M, Ray NF, Chan JK, Chesnut CH III, Einhorn TA, Johnston CC, Raisz LG, Silverman SL, Siris ES (1997) Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation. J Bone Miner Res 12:16–23PubMedCrossRefGoogle Scholar
  9. 9.
    Kanis JA, Oden A, Johnell O, Jonsson B, De LC, Dawson A (2001) The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int 12:417–427PubMedCrossRefGoogle Scholar
  10. 10.
    Kanis JA, Oden A, Johnell O, De LC, Jonsson B, Oglesby AK (2003) The components of excess mortality after hip fracture. Bone 32:468–473PubMedCrossRefGoogle Scholar
  11. 11.
    Kanis JA, Oden A, Johnell O, De LC, Jonsson B (2004) Excess mortality after hospitalisation for vertebral fracture. Osteoporos Int 15:108–112PubMedCrossRefGoogle Scholar
  12. 12.
    Anonymous (2009) Institut National de la Statistique et des Etudes Economiques.
  13. 13.
    Anonymous (2009) Institut National des Edudes Demographiques.
  14. 14.
    Couris CM, Chapurlat RD, Kanis JA, Burlet N, Delmas PD, Schott AM (2012) FRAX probabilities and risk of major osteoporotic fracture in France. Osteopooros Int 23:2321–7CrossRefGoogle Scholar
  15. 15.
    Stevenson M, Jones ML, De NE, Brewer N, Davis S, Oakley J (2005) A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess 9:1–160PubMedGoogle Scholar
  16. 16.
    Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA III, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721–739PubMedCrossRefGoogle Scholar
  17. 17.
    Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De LC, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmo. Osteoporos Int 11:669–674PubMedCrossRefGoogle Scholar
  18. 18.
    Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254–1259PubMedCrossRefGoogle Scholar
  19. 19.
    Kanis JA, Johnell O, De LC, Johansson H, Oden A, Delmas P, Eisman J, Fujiwara S, Garnero P, Kroger H, McCloskey EV, Mellstrom D, Melton LJ, Pols H, Reeve J, Silman A, Tenenhouse A (2004) A meta-analysis of previous fracture and subsequent fracture risk. Bone 35:375–382PubMedCrossRefGoogle Scholar
  20. 20.
    Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, Johnston CC Jr, Lindsay R (1998) Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8:468–489PubMedCrossRefGoogle Scholar
  21. 21.
    Haute Autorité de la Santé (2006) Prévention, diagnostic et traitement de l’ostéoporose. Haute Autorité de la SantéGoogle Scholar
  22. 22.
    Cooper C, Cole ZA, Holroyd CR, Earl SC, Harvey NC, Dennison EM, Melton LJ, Cummings SR, Kanis JA (2011) Secular trends in the incidence of hip and other osteoporotic fractures. Osteoporos Int 22:1277–1288PubMedCrossRefGoogle Scholar
  23. 23.
    Gullberg B, Johnell O, Kanis JA (1997) World-wide projections for hip fracture. Osteoporos Int 7:407–413PubMedCrossRefGoogle Scholar
  24. 24.
    Melton LJ III, Kanis JA, Johnell O (2005) Potential impact of osteoporosis treatment on hip fracture trends. J Bone Miner Res 20:895–897PubMedCrossRefGoogle Scholar
  25. 25.
    Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, Cauley JA, Compston JE, Dawson-Hughes B, El-Hajj FG, Johansson H, Leslie WD, Lewiecki EM, Luckey M, Oden A, Papapoulos SE, Poiana C, Rizzoli R, Wahl DA, McCloskey EV (2011) Interpretation and use of FRAX in clinical practice. Osteoporos Int 22:2395–2411PubMedCrossRefGoogle Scholar

Copyright information

© International Osteoporosis Foundation and National Osteoporosis Foundation 2012

Authors and Affiliations

  • H. Cawston
    • 1
  • M. Maravic
    • 2
    • 3
  • P. Fardellone
    • 4
  • A. Gauthier
    • 5
  • J. A. Kanis
    • 6
  • J. Compston
    • 7
  • F. Borgström
    • 8
    • 9
  • C. Cooper
    • 10
    • 11
  • E. McCloskey
    • 6
  1. 1.OptumInsightNanterreFrance
  2. 2.Département d’information médicaleHôpital Léopold BellanParis Cedex 14France
  3. 3.3M CONSEILSParisFrance
  4. 4.CHU AmiensUnité INSERM 12AmiensFrance
  5. 5.AmarisLondonUK
  6. 6.University of SheffieldSheffieldUK
  7. 7.School of Clinical MedicineUniversity of CambridgeCambridgeUK
  8. 8.OptumInsightStockholmSweden
  9. 9.LIME/MMC, Karolinska InstitutetStockholmSweden
  10. 10.University of SouthamptonSouthamptonUK
  11. 11.University of OxfordOxfordUK

Personalised recommendations